HPV Testing and Pap Test Market Size, Growth, Share & Trends Analysis
Human Papilloma Virus/HPV Test and Pap Smear/Test Market by Product & Service (Consumables, Instruments), Test Type (Follow-up, Co-testing, Primary HPV), Technology (MDx, Cytology), Application (Vaginal, Cervical), Care Setting - Global Forecast to 2030
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The HPV testing and Pap test market is estimated at USD 2.44 billion in 2025 and is projected to reach USD 3.94 billion by 2030, growing at a CAGR of 10.0% during the forecast period. The HPV testing and Pap test market is strongly driven by a combination of rising HPV cases, growing awareness of cervical cancer screening programs, and increasing R&D funding for cervical cancer prevention. The growing prevalence of HPV infections is contributing to a higher incidence of cervical cancer, creating a critical need for effective early detection through HPV and Pap testing. At the same time, public health campaigns, government-led initiatives, and educational programs are raising awareness about the importance of regular screening, encouraging greater participation in preventive testing. Increasing investments in research and development are further supporting the advancement of more sensitive and accurate diagnostic tools, including molecular HPV assays and automated cytology platforms. Collectively, these factors are expanding testing adoption, improving early detection rates, and strengthening the overall growth of the global HPV testing and Pap test market.
KEY TAKEAWAYS
-
BY PRODUCT & SERVICEBy product & service, the market is segmented into consumables, instruments, and services. Consumables dominate the market, driven by their recurring use in HPV and Pap testing, including reagents, collection kits, and assay-specific materials. The growing adoption of cervical cancer screening programs, rising awareness of early detection, and regulatory guidelines mandating standardized testing protocols reinforce the strong demand for consumables. Instruments and services support laboratory workflows, but consumables remain the largest contributor to market revenue.
-
BY TEST TYPEBy test type, the market is divided into HPV testing and Pap tests, with HPV testing holding the largest share. This dominance is driven by its higher sensitivity and ability to detect high-risk HPV strains before lesions develop, making it the preferred method for early cervical cancer detection. Pap tests remain widely used, primarily as a complementary tool for cytology confirmation. The rising prevalence of HPV infections, coupled with growing awareness of preventive care, has intensified the demand for HPV testing. Preventive health initiatives and organized screening programs continue to support HPV testing as the primary driver of market growth.
-
BY TECHNOLOGYBased on technology, the market segmentation includes molecular diagnostics, immunodiagnostics, and cytology, with molecular diagnostics leading the market. Its high accuracy, sensitivity, and ability to provide rapid detection of high-risk HPV strains make it the preferred choice in hospitals and laboratories. Techniques such as PCR, high-throughput assays, and automated testing platforms have expanded adoption and efficiency. The integration of digital data management and automated workflow systems enhances accuracy and reduces human error, further strengthening this segment’s position. The rising demand for precise and reliable testing solutions continues to drive molecular diagnostics as the fastest-growing technology.
-
BY APPLICATIONBased on application, the HPV testing and Pap test market is segmented into cervical cancer screening and vaginal cancer screening. Cervical cancer screening currently dominates the market due to its high prevalence and well-established screening guidelines. The growing awareness of cervical cancer and preventive healthcare programs drives widespread adoption of HPV and Pap tests. While vaginal cancer screening is emerging, the majority of testing volumes remain focused on cervical cancer detection, reinforcing its position as the primary application segment in the market.
-
BY CARE SETTINGThe HPV testing and Pap test market, by care setting, is segmented into hospitals, diagnostic laboratories, and physicians' offices & clinics. Hospitals lead the market due to their high patient volumes, advanced diagnostic facilities, and central role in organized cervical cancer screening programs. Their ability to adopt automated molecular assays and integrated testing platforms ensures accurate and timely results, driving consistent demand. The combination of infrastructure, skilled personnel, and participation in preventive healthcare initiatives positions hospitals as the largest care setting segment in the market.
The HPV testing and Pap test market is set to experience strong growth in the coming years, driven by increasing demand for accurate and early detection of HPV infections, rising prevalence of cervical cancer, and continuous advancements in diagnostic technologies. Molecular assays, automated cytology platforms, and high-throughput testing systems are being increasingly adopted to enable precise identification of high-risk HPV strains, support timely clinical interventions, and improve patient outcomes. The growing incidence of HPV infections, coupled with greater awareness of cervical cancer and preventive screening programs, is further fueling market adoption. Additionally, the expansion of healthcare infrastructure, rising healthcare expenditure, and the integration of advanced testing solutions are enhancing the efficiency, reliability, and accessibility of HPV and Pap testing.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The HPV testing and Pap test market is undergoing significant changes driven by increasing awareness of cervical cancer, rising HPV prevalence, and advancements in diagnostic technologies. Hospitals, diagnostic laboratories, and physicians’ offices & clinics form the primary customer base for HPV and Pap testing solutions. Key trends, including the growing demand for accurate and early detection, increasing adoption of molecular assays and automated cytology platforms, and evolving regulatory standards, are reshaping laboratory workflows and testing strategies. These developments directly influence the procurement of consumables, instruments, and testing services, thereby impacting the growth prospects and market share of HPV and Pap test solution providers.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Level
-
Rising HPV cases and subsequent increase in cervical cancer
-
Growing awareness of cervical cancer screening programs
Level
-
Growing awareness of HPV vaccination
Level
-
Regulatory guidelines for cervical cancer screening
-
Innovative improvements in HPV tests
Level
-
Uncertain reimbursement scenario
-
Stringent regulatory & legal requirements
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Rising HPV cases and subsequent increase in cervical cancer
The increasing prevalence of HPV infections is contributing to a higher incidence of cervical cancer worldwide. High-risk HPV strains are the leading cause of these cancers, highlighting the urgent need for early detection. This has boosted demand for reliable HPV and Pap tests, as timely screening enables intervention before disease progression. Preventive health initiatives and screening programs are further encouraging test adoption, reinforcing the critical role of HPV and Pap testing in reducing cervical cancer incidence and improving women’s health outcomes.
Restraint: Growing awareness of HPV vaccination
The increasing awareness and adoption of HPV vaccination is constraining the growth of the HPV testing and Pap test market. As vaccination coverage rises, the prevalence of high-risk HPV infections declines, reducing the immediate demand for frequent screening. While vaccination is crucial for preventing cervical cancer, it can limit the short-term expansion of HPV and Pap testing, particularly in regions with widespread immunization programs.
Opportunity: Innovative improvements in HPV tests
Ongoing innovations in HPV testing are boosting market growth by enhancing accuracy, sensitivity, and ease of use. Advances such as high-throughput molecular assays, automated cytology platforms, and integrated data management systems enable faster and more reliable detection of high-risk HPV strains. These technological improvements support broader adoption in hospitals, laboratories, and clinics, helping healthcare providers improve early detection and patient outcomes.
Challenge: Stringent regulatory & legal requirements
The HPV testing and Pap test market faces challenges due to stringent regulatory and legal requirements. Compliance with rigorous approval processes, quality standards, and accreditation norms can increase the time and cost associated with bringing new tests and platforms to market. These regulatory hurdles may slow product launches, limit market entry for smaller players, and pose challenges in expanding testing programs across different regions.
Human Papilloma Virus/HPV Test and Pap Smear/Test Market: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Provides automated cytology and molecular diagnostics platforms for HPV and Pap testing, including high-throughput screening for cervical cancer | High sensitivity and specificity, automated workflows reduce errors, supports large-scale screening programs, faster turnaround times, improved patient outcomes, integration with lab information systems |
 |
Offers HPV and Pap tests, specimen collection devices, reagents, and workflow solutions for both HPV and Pap testing in hospitals and diagnostic laboratories | Reliable sample collection, supports both HPV and Pap testing, compatible with multiple platforms, streamlines lab workflow, improves test accuracy, enhances lab efficiency, supports preventive healthcare initiatives |
 |
Provides automated molecular diagnostics platforms for HPV testing, including the cobas HPV Test for primary cervical cancer screening | High accuracy in detecting high-risk HPV strains, integration with automated platforms, supports large-scale screening programs, reduces turnaround time, enhances early detection, improves clinical decision-making |
 |
Offers molecular testing solutions for HPV detection, including real-time PCR assays and integrated sample-to-result platforms | High reproducibility and sensitivity, automated solutions reduce errors, enables high-throughput testing, supports population-level screening, flexible integration into existing lab workflows, improves early detection |
 |
Provides molecular diagnostics solutions for HPV testing, including instruments and reagents for hospitals and diagnostic labs | Reliable molecular assays, automated systems streamline workflow, supports high-throughput testing, enhances accuracy and reproducibility, improves lab efficiency, enables timely cervical cancer detection |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The HPV testing and Pap test market serves a diverse range of end users, including hospitals, diagnostic laboratories, and physicians’ offices & clinics. Testing primarily focuses on cervical cancer screening, with emerging applications in vaginal cancer screening. The uptake of HPV and Pap testing is driven by advancements in molecular diagnostics, automated cytology platforms, and integrated data management systems, which improve accuracy, throughput, and workflow efficiency. Increasing regulatory approvals, national screening programs, and preventive healthcare initiatives are fostering innovation and expanding clinical applications across different end-user segments.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
HPV Testing and Pap Test Market, By Product & Service
Based on product & service, the HPV testing and Pap test market is categorized into consumables, instruments, and services. Consumables form a critical segment of the HPV testing and Pap test market. This includes reagents, collection kits, and assay-specific materials required for both HPV and Pap testing. The segment’s growth is driven by the increasing adoption of screening programs, rising awareness of early detection, and the recurring need for high-quality consumables to ensure accurate and reproducible results. Regulatory guidelines mandating standardized testing further reinforce the demand for consumables, making this segment the largest contributor to the market.
HPV Testing and Pap Test Market, By Test Type
The market is divided into HPV testing and Pap tests, with HPV testing holding the largest share. This dominance is driven by its higher sensitivity and ability to detect high-risk HPV strains before lesions develop, making it the preferred method for early cervical cancer detection. Pap tests remain widely used, primarily as a complementary tool for cytology confirmation. The rising prevalence of HPV infections, coupled with growing awareness of preventive care, has intensified demand for HPV testing. Preventive health initiatives and organized screening programs continue to support HPV testing as the primary driver of market growth.
HPV Testing and Pap Test Market, By Technology
Based on technology, the market segmentation includes molecular diagnostics, immunodiagnostics, and cytology, with molecular diagnostics leading the market. Its high accuracy, sensitivity, and ability to provide rapid detection of high-risk HPV strains make it the preferred choice in hospitals and laboratories. Techniques such as PCR, high-throughput assays, and automated testing platforms have expanded adoption and efficiency. The integration of digital data management and automated workflow systems enhances accuracy and reduces human error, further strengthening this segment’s position. Rising demand for precise and reliable testing solutions continues to drive molecular diagnostics as the fastest-growing technology.
HPV Testing and Pap Test Market, By Application
Based on application, the HPV testing and Pap test market is categorized into cervical cancer screening and vaginal cancer screening. Cervical cancer screening currently dominates the market due to its high prevalence and well-established screening guidelines. The growing awareness of cervical cancer and preventive healthcare programs drives widespread adoption of HPV and Pap tests. While vaginal cancer screening is emerging, the majority of testing volumes remain focused on cervical cancer detection, reinforcing its position as the primary application segment in the market.
HPV Testing and Pap Test Market, By Care Setting
The HPV testing and Pap test market, by care setting, is segmented into hospitals, diagnostic laboratories, and physicians' offices & clinics. Hospitals lead the market due to their high patient volumes, advanced diagnostic facilities, and central role in organized cervical cancer screening programs. Their ability to adopt automated molecular assays and integrated testing platforms ensures accurate and timely results, driving consistent demand. The combination of infrastructure, skilled personnel, and participation in preventive healthcare initiatives positions hospitals as the largest care setting segment in the market.
REGION
North America accounted for largest share of global HPV testing and Pap test market during forecast period.
The HPV testing and Pap test market in North America is growing due to the high awareness of cervical cancer, increasing adoption of preventive healthcare programs, and widespread use of advanced technologies such as molecular diagnostics and automated cytology platforms. Additionally, a well-established healthcare infrastructure, rising healthcare expenditure, and strong government and private-sector initiatives to expand cervical cancer screening are further driving market growth in the region.
Human Papilloma Virus/HPV Test and Pap Smear/Test Market: COMPANY EVALUATION MATRIX
Hologic, Inc. is a leading player in the HPV testing and Pap test market, supported by its comprehensive portfolio of molecular and cytology-based screening solutions. With a strong presence in North America and operations in multiple international markets, Hologic effectively addresses diverse cervical cancer screening needs worldwide. Its partnerships with hospitals, diagnostic laboratories, and public health organizations strengthen its ability to meet evolving screening demands and support large-scale preventive healthcare initiatives in both developed and emerging regions.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size Value in 2024 (Value) | USD 2.29 Billion |
| Market Forecast in 2030 (Value) | USD 3.94 Billion |
| Growth Rate | CAGR of 10.0% from 2025–2030 |
| Years Considered | 2023–2030 |
| Base Year | 2024 |
| Forecast Period | 2025–2030 |
| Units Considered | Value (USD Million), Volume (Million) |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | By Product & Service (Consumables, Instruments, and Services), Test Type [HPV Testing (Primary HPV Testing, Co-testing, and Follow-up HPV Testing) and Pap Tests], Technology (Molecular Diagnostics, Immunodiagnostics, and Cytology), Application (Cervical Cancer Screening and Vaginal Cancer Screening), Care Setting (Hospitals, Diagnostic Laboratories, and Physicians’ Offices & Clinics) |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
WHAT IS IN IT FOR YOU: Human Papilloma Virus/HPV Test and Pap Smear/Test Market REPORT CONTENT GUIDE
RECENT DEVELOPMENTS
- December 2024 : The Federal Government of Nigeria signed an agreement with Abbott Laboratories GmbH, Siemens Healthineers AG (Germany), and its Nigerian partner Tanit Medical Engineering to enhance healthcare access and capacity in Nigeria.
- October 2024 : Becton, Dickinson and Company (BD) (US) received Health Canada approval for its BD Onclarity HPV Assay for human papillomavirus (HPV) testing for use with self-collected vaginal specimens at home.
- June 2024 : The WHO awarded F. Hoffmann-La Roche Ltd.'s (Switzerland) cobas HPV test the prequalification designations for use on the cobas 5800 system and for self-collected samples on the cobas 5800, 6800, and 8800 systems.
- February 2024 : Becton, Dickinson and Company (BD) (US) partnered with Camtech Health, a digital health company focused on at-home health testing, to advance cervical cancer screening by offering the first-ever option for women in Singapore to self-collect a sample in the privacy of their own home. The program combines the Camtech Health HPV (human papillomavirus) test for self-collection with the BD Onclarity HPV Assay, which is a clinically validated test that can simultaneously detect 14 high-risk HPV strains (or "genotypes"). The program objective is to improve the rate of cervical cancer screening in Singapore.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 30)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKETS COVERED
FIGURE 1 HPV TESTING MARKET SEGMENTATION
1.3.1 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 34)
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 2 HPV TESTING MARKET: RESEARCH DESIGN
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Primary sources
2.2.2.2 Key data from primary sources
2.2.2.3 Key industry insights
2.2.2.4 Breakdown of primary interviews
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation approach
FIGURE 5 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.3.1.2 Approach 2: Presentations of companies and primary interviews
2.3.1.3 CAGR projections
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3.2 TOP-DOWN APPROACH
FIGURE 7 HPV TESTING MARKET: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 8 DATA TRIANGULATION METHODOLOGY
2.5 MARKET SHARE ANALYSIS
2.6 STUDY ASSUMPTIONS
2.7 GROWTH RATE ASSUMPTIONS
2.8 RISK ASSESSMENT
2.8.1 HPV TESTING MARKET: RISK ASSESSMENT
3 EXECUTIVE SUMMARY (Page No. - 45)
FIGURE 9 HPV TESTING MARKET, BY TEST TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 10 HPV TESTING MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
FIGURE 11 HPV TESTING MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 12 HPV TESTING MARKET, BY REGION, 2022 VS. 2027 (USD MILLION)
4 PREMIUM INSIGHTS (Page No. - 48)
4.1 HPV TESTING MARKET OVERVIEW
FIGURE 13 RISING CASES OF HPV AND INCREASING R&D INITIATIVES ON CERVICAL CANCER SCREENING TO DRIVE MARKET
4.2 HPV TESTING MARKET SHARE, BY TEST TYPE, 2022 VS. 2027
FIGURE 14 HPV TESTING SEGMENT TO CONTINUE TO DOMINATE MARKET DURING FORECAST PERIOD
4.3 HPV TESTING MARKET SHARE, BY APPLICATION, 2022 VS. 2027
FIGURE 15 CERVICAL CANCER SCREENING SEGMENT TO CONTINUE TO DOMINATE MARKET DURING FORECAST PERIOD
4.4 HPV TESTING MARKET SHARE, BY END USER, 2022 VS. 2027
FIGURE 16 HOSPITALS TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD
4.5 HPV TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 17 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 51)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 18 HPV TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising HPV cases and subsequent increase in cervical cancer
5.2.1.2 Growing awareness of cervical cancer screening programs
5.2.1.3 Increasing R&D funding initiatives on cervical cancer prevention
5.2.2 RESTRAINTS
5.2.2.1 Growing awareness of HPV vaccination
5.2.3 OPPORTUNITIES
5.2.3.1 Regulatory guidelines for cervical cancer screening
5.2.3.2 Innovative improvements in HPV tests
5.2.3.2.1 Introduction of HPV primary screening tests
5.2.3.2.2 Technological improvements in HPV tests
5.2.4 CHALLENGES
5.2.4.1 Uncertain reimbursement scenario
5.2.4.2 Stringent regulatory & legal requirements
5.2.4.3 Operational barriers
5.3 PRICING ANALYSIS
TABLE 1 PRICE OF HPV TESTING AND PAP TEST PRODUCTS (2021)
5.4 PATENT ANALYSIS
FIGURE 19 PATENT ANALYSIS OF PAP TEST MARKET
5.5 VALUE CHAIN ANALYSIS
FIGURE 20 VALUE CHAIN ANALYSIS OF PAP TEST MARKET: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
5.6 SUPPLY CHAIN ANALYSIS
FIGURE 21 PAP TEST MARKET: SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM/MARKET MAP
FIGURE 22 PAP TEST MARKET: ECOSYSTEM/MARKET MAP
5.7.1 PAP TEST MARKET: ROLE IN ECOSYSTEM
5.8 PORTER’S FIVE FORCES ANALYSIS
TABLE 2 HPV TEST MARKET: PORTER’S FIVE FORCES ANALYSIS
5.8.1 THREAT OF NEW ENTRANTS
5.8.2 THREAT OF SUBSTITUTES
5.8.3 BARGAINING POWER OF BUYERS
5.8.4 BARGAINING POWER OF SUPPLIERS
5.8.5 DEGREE OF COMPETITION
5.9 TRADE ANALYSIS
5.9.1 TRADE ANALYSIS FOR DIAGNOSTIC OR LABORATORY REAGENTS
TABLE 3 IMPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS, BY COUNTRY, 2017–2021 (USD MILLION)
TABLE 4 EXPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS, BY COUNTRY, 2017–2021 (USD MILLION)
5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.10.1 REVENUE SOURCES SHIFTING TOWARD TECHNOLOGY-BASED SOLUTIONS DUE TO COVID-19
FIGURE 23 REVENUE SHIFT IN HPV TEST MARKET
6 HPV TESTING AND PAP TEST MARKET, BY TEST TYPE (Page No. - 65)
6.1 INTRODUCTION
TABLE 5 HPV TEST MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)
TABLE 6 HPV TEST MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)
TABLE 7 HPV TEST MARKET, BY TEST TYPE, 2017–2020 (MILLION KITS)
TABLE 8 HPV TEST MARKET, BY TEST TYPE, 2021–2027 (MILLION KITS)
6.2 HPV TESTING
TABLE 9 HPV TESTING MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)
TABLE 10 HPV TESTING MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)
TABLE 11 HPV TESTING MARKET, BY REGION, 2017–2020 (USD MILLION)
TABLE 12 HPV TESTING MARKET, BY REGION, 2021–2027 (USD MILLION)
6.2.1 FOLLOW-UP HPV TESTING
6.2.1.1 Irregular Pap test results to drive adoption
TABLE 13 FOLLOW-UP HPV TESTING MARKET, BY REGION, 2017–2020 (USD MILLION)
TABLE 14 FOLLOW-UP HPV TESTING MARKET, BY REGION, 2021–2027 (USD MILLION)
6.2.2 CO-TESTING
6.2.2.1 Co-testing to drive rapid detection results for cervical cancer
TABLE 15 HPV CO-TESTING MARKET, BY REGION, 2017–2020 (USD MILLION)
TABLE 16 HPV CO-TESTING MARKET, BY REGION, 2021–2027 (USD MILLION)
6.2.3 PRIMARY HPV TESTING
6.2.3.1 Test sensitivity and accuracy to drive segment growth
TABLE 17 PRIMARY HPV TESTING MARKET, BY REGION, 2017–2020 (USD MILLION)
TABLE 18 PRIMARY HPV TESTING MARKET, BY REGION, 2021–2027 (USD MILLION)
6.3 PAP TEST
6.3.1 RISING CASES OF FALSE-NEGATIVE TESTS TO RESTRAIN MARKET
TABLE 19 PAP TEST MARKET, BY REGION, 2017–2020 (USD MILLION)
TABLE 20 PAP TEST MARKET, BY REGION, 2021–2027 (USD MILLION)
7 HPV TESTING AND PAP TEST MARKET, BY APPLICATION (Page No. - 74)
7.1 INTRODUCTION
TABLE 21 MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 22 MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
7.2 CERVICAL CANCER SCREENING
7.2.1 RISING INCIDENCE OF CERVICAL CANCER TO DRIVE MARKET
TABLE 23 MARKET FOR CERVICAL CANCER SCREENING, BY REGION, 2017–2020 (USD MILLION)
TABLE 24 MARKET FOR CERVICAL CANCER SCREENING, BY REGION, 2021–2027 (USD MILLION)
7.3 VAGINAL CANCER SCREENING
7.3.1 LIMITED SCREENING TESTS TO RESTRAIN MARKET
TABLE 25 MARKET FOR VAGINAL CANCER SCREENING, BY REGION, 2017–2020 (USD MILLION)
TABLE 26 MARKET FOR VAGINAL CANCER SCREENING, BY REGION, 2021–2027 (USD MILLION)
8 HPV TESTING AND PAP TEST MARKET, BY END USER (Page No. - 78)
8.1 INTRODUCTION
TABLE 27 HPV TEST AND PAP TEST MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 28 HPV TEST AND PAP TEST MARKET, BY END USER, 2021–2027 (USD MILLION)
8.2 HOSPITALS
8.2.1 ADVANCED TECHNOLOGIES AND EQUIPPED FACILITIES TO DRIVE MARKET
TABLE 29 HPV TEST AND PAP TEST MARKET FOR HOSPITALS, BY REGION, 2017–2020 (USD MILLION)
TABLE 30 HPV TEST AND PAP TEST MARKET FOR HOSPITALS, BY REGION, 2021–2027 (USD MILLION)
8.3 LABORATORIES
8.3.1 INCREASING OUTSOURCING OF DIAGNOSTIC TESTS TO LABORATORIES TO DRIVE MARKET
TABLE 31 HPV TEST AND PAP TEST MARKET FOR LABORATORIES, BY REGION, 2017–2020 (USD MILLION)
TABLE 32 HPV TEST AND PAP TEST MARKET FOR LABORATORIES, BY REGION, 2021–2027 (USD MILLION)
8.4 PHYSICIANS’ OFFICES AND CLINICS
8.4.1 RAPID AND EFFICIENT RESULTS TO SUPPORT MARKET GROWTH
TABLE 33 HPV TEST AND PAP TEST MARKET FOR PHYSICIANS’ OFFICES AND CLINICS, BY REGION, 2017–2020 (USD MILLION)
TABLE 34 HPV TEST AND PAP TEST MARKET FOR PHYSICIANS’ OFFICES AND CLINICS, BY REGION, 2021–2027 (USD MILLION)
9 HPV TESTING AND PAP TEST MARKET, BY REGION (Page No. - 84)
9.1 INTRODUCTION
TABLE 35 GLOBAL MARKET, BY REGION, 2017–2020 (USD MILLION)
TABLE 36 GLOBAL MARKET, BY REGION, 2021–2027 (USD MILLION)
9.2 NORTH AMERICA
FIGURE 24 NORTH AMERICA: MARKET SNAPSHOT
TABLE 37 NORTH AMERICA: MARKET, BY COUNTRY, 2017–2020 (USD MILLION)
TABLE 38 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2027 (USD MILLION)
TABLE 39 NORTH AMERICA: MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)
TABLE 40 NORTH AMERICA: MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)
TABLE 41 NORTH AMERICA: MARKET, BY TEST TYPE, 2017–2020 (MILLION KITS)
TABLE 42 NORTH AMERICA: MARKET, BY TEST TYPE, 2021–2027 (MILLION KITS)
TABLE 43 NORTH AMERICA: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 44 NORTH AMERICA: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)
TABLE 45 NORTH AMERICA: MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 46 NORTH AMERICA: MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 47 NORTH AMERICA: MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 48 NORTH AMERICA: MARKET, BY END USER, 2021–2027 (USD MILLION)
9.2.1 US
9.2.1.1 Rising government initiatives for cancer research to drive market
TABLE 49 US: MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)
TABLE 50 US: MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)
TABLE 51 US: MARKET, BY TEST TYPE, 2017–2020 (MILLION KITS)
TABLE 52 US: MARKET, BY TEST TYPE, 2021–2027 (MILLION KITS)
TABLE 53 US: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 54 US: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)
TABLE 55 US: MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 56 US: MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 57 US: MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 58 US: MARKET, BY END USER, 2021–2027 (USD MILLION)
9.2.2 CANADA
9.2.2.1 Government support in raising awareness on cervical cancer screening to support market growth
TABLE 59 CANADA: MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)
TABLE 60 CANADA: MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)
TABLE 61 CANADA: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 62 CANADA: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)
TABLE 63 CANADA: MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 64 CANADA: MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 65 CANADA: MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 66 CANADA: MARKET, BY END USER, 2021–2027 (USD MILLION)
9.3 EUROPE
TABLE 67 EUROPE: MARKET, BY COUNTRY, 2017–2020 (USD MILLION)
TABLE 68 EUROPE: MARKET, BY COUNTRY, 2021–2027 (USD MILLION)
TABLE 69 EUROPE: MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)
TABLE 70 EUROPE: MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)
TABLE 71 EUROPE: MARKET, BY TEST TYPE, 2017–2020 (MILLION KITS)
TABLE 72 EUROPE: MARKET, BY TEST TYPE, 2021–2027 (MILLION KITS)
TABLE 73 EUROPE: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 74 EUROPE: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)
TABLE 75 EUROPE: MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 76 EUROPE: MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 77 EUROPE: MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 78 EUROPE: MARKET, BY END USER, 2021–2027 (USD MILLION)
9.3.1 GERMANY
9.3.1.1 Established healthcare infrastructure and rising government spending on cancer screening to drive market
TABLE 79 GERMANY: MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)
TABLE 80 GERMANY: MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)
TABLE 81 GERMANY: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 82 GERMANY: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)
TABLE 83 GERMANY: MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 84 GERMANY: MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 85 GERMANY: MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 86 GERMANY: MARKET, BY END USER, 2021–2027 (USD MILLION)
9.3.2 UK
9.3.2.1 Rising focus on research projects for specific cancers to drive market
TABLE 87 UK: MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)
TABLE 88 UK: MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)
TABLE 89 UK: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 90 UK: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)
TABLE 91 UK: MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 92 UK: MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 93 UK: MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 94 UK: MARKET, BY END USER, 2021–2027 (USD MILLION)
9.3.3 FRANCE
9.3.3.1 High incidence of cervical cancer and associated investments in genomics to support market growth
TABLE 95 FRANCE: MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)
TABLE 96 FRANCE: MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)
TABLE 97 FRANCE: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 98 FRANCE: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)
TABLE 99 FRANCE: MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 100 FRANCE: MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 101 FRANCE: MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 102 FRANCE: MARKET, BY END USER, 2021–2027 (USD MILLION)
9.3.4 SPAIN
9.3.4.1 Increasing research on cancer diagnostics to support market growth
TABLE 103 SPAIN: MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)
TABLE 104 SPAIN: MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)
TABLE 105 SPAIN: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 106 SPAIN: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)
TABLE 107 SPAIN: MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 108 SPAIN: MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 109 SPAIN: MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 110 SPAIN: MARKET, BY END USER, 2021–2027 (USD MILLION)
9.3.5 ITALY
9.3.5.1 Growing acceptance of molecular-based diagnostic tests for cervical cancer screening to drive market
TABLE 111 ITALY: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)
TABLE 112 ITALY: MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)
TABLE 113 ITALY: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 114 ITALY: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)
TABLE 115 ITALY: MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 116 ITALY: MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 117 ITALY: MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 118 ITALY: MARKET, BY END USER, 2021–2027 (USD MILLION)
9.3.6 REST OF EUROPE
TABLE 119 REST OF EUROPE: MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)
TABLE 120 REST OF EUROPE: MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)
TABLE 121 REST OF EUROPE: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 122 REST OF EUROPE: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)
TABLE 123 REST OF EUROPE: MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 124 REST OF EUROPE: MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 125 REST OF EUROPE: MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 126 REST OF EUROPE: MARKET, BY END USER, 2021–2027 (USD MILLION)
9.4 ASIA PACIFIC
FIGURE 25 ASIA PACIFIC: MARKET SNAPSHOT
TABLE 127 ASIA PACIFIC: MARKET, BY COUNTRY, 2017–2020 (USD MILLION)
TABLE 128 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2027 (USD MILLION)
TABLE 129 ASIA PACIFIC: MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)
TABLE 130 ASIA PACIFIC: MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)
TABLE 131 ASIA PACIFIC: MARKET, BY TEST TYPE, 2017–2020 (MILLION KITS)
TABLE 132 ASIA PACIFIC: MARKET, BY TEST TYPE, 2021–2027 (MILLION KITS)
TABLE 133 ASIA PACIFIC: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 134 ASIA PACIFIC: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)
TABLE 135 ASIA PACIFIC: MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 136 ASIA PACIFIC: MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 137 ASIA PACIFIC: MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 138 ASIA PACIFIC: MARKET, BY END USER, 2021–2027 (USD MILLION)
9.4.1 CHINA
9.4.1.1 Government initiatives for cancer diagnosis and immunotherapy to support market growth
TABLE 139 CHINA: MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)
TABLE 140 CHINA: MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)
TABLE 141 CHINA: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 142 CHINA: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)
TABLE 143 CHINA: MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 144 CHINA: MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 145 CHINA: MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 146 CHINA: MARKET, BY END USER, 2021–2027 (USD MILLION)
9.4.2 JAPAN
9.4.2.1 Rising demand for technologically advanced cervical cancer screening tests to drive market
TABLE 147 JAPAN: MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)
TABLE 148 JAPAN: MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)
TABLE 149 JAPAN: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 150 JAPAN: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)
TABLE 151 JAPAN: MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 152 JAPAN: MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 153 JAPAN: MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 154 JAPAN: MARKET, BY END USER, 2021–2027 (USD MILLION)
9.4.3 INDIA
9.4.3.1 High cancer burden and rising pharmaceutical industry to drive market
TABLE 155 INDIA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)
TABLE 156 INDIA: MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)
TABLE 157 INDIA: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 158 INDIA: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)
TABLE 159 INDIA: MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 160 INDIA: MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 161 INDIA: MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 162 INDIA: MARKET, BY END USER, 2021–2027 (USD MILLION)
9.4.4 REST OF ASIA PACIFIC
TABLE 163 REST OF ASIA PACIFIC: MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)
TABLE 164 REST OF ASIA PACIFIC: MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)
TABLE 165 REST OF ASIA PACIFIC: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 166 REST OF ASIA PACIFIC: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)
TABLE 167 REST OF ASIA PACIFIC: MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 168 REST OF ASIA PACIFIC: MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 169 REST OF ASIA PACIFIC: MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 170 REST OF ASIA PACIFIC: MARKET, BY END USER, 2021–2027 (USD MILLION)
9.5 LATIN AMERICA
9.5.1 RISING AWARENESS OF ADVANCED CANCER SCREENING TECHNOLOGIES TO DRIVE MARKET
TABLE 171 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)
TABLE 172 LATIN AMERICA: MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)
TABLE 173 LATIN AMERICA: MARKET, BY TEST TYPE, 2017–2020 (MILLION KITS)
TABLE 174 LATIN AMERICA: MARKET, BY TEST TYPE, 2021–2027 (MILLION KITS)
TABLE 175 LATIN AMERICA: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 176 LATIN AMERICA: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)
TABLE 177 LATIN AMERICA: HPV TES AND PAP TEST MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 178 LATIN AMERICA: HPV TES AND PAP TEST MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 179 LATIN AMERICA: HPV TES AND PAP TEST MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 180 LATIN AMERICA: HPV TES AND PAP TEST MARKET, BY END USER, 2021–2027 (USD MILLION)
9.6 MIDDLE EAST AND AFRICA
9.6.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE DUE TO HIGH CANCER BURDEN TO SUPPORT MARKET GROWTH
TABLE 181 MIDDLE EAST AND AFRICA: HPV TES AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)
TABLE 182 MIDDLE EAST AND AFRICA: HPV TES AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)
TABLE 183 MIDDLE EAST AND AFRICA: HPV TEST AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (MILLION KITS)
TABLE 184 MIDDLE EAST AND AFRICA: HPV TEST AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (MILLION KITS)
TABLE 185 MIDDLE EAST AND AFRICA: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 186 MIDDLE EAST AND AFRICA: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)
TABLE 187 MIDDLE EAST AND AFRICA: HPV TES AND PAP TEST MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 188 MIDDLE EAST AND AFRICA: HPV TES AND PAP TEST MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 189 MIDDLE EAST AND AFRICA: HPV TES AND PAP TEST MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 190 MIDDLE EAST AND AFRICA: HPV TES AND PAP TEST MARKET, BY END USER, 2021–2027 (USD MILLION)
10 COMPETITIVE LANDSCAPE (Page No. - 148)
10.1 OVERVIEW
10.2 STRATEGIES ADOPTED BY KEY PLAYERS
10.2.1 HPV TESTING AND PAP TEST MARKET: OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
TABLE 191 OVERVIEW OF STRATEGIES ADOPTED BY KEY HPV TESTING AND PAP TEST PLAYERS
10.3 REVENUE SHARE ANALYSIS OF LEADING MARKET PLAYERS
FIGURE 26 REVENUE SHARE ANALYSIS OF LEADING MARKET PLAYERS
10.4 MARKET SHARE ANALYSIS
FIGURE 27 GLOBAL MARKET SHARE, BY KEY PLAYER (2021)
TABLE 192 GLOBAL MARKET: DEGREE OF COMPETITION
10.5 COMPANY EVALUATION QUADRANT
10.5.1 LIST OF EVALUATED VENDORS
10.5.2 STARS
10.5.3 EMERGING LEADERS
10.5.4 PERVASIVE PLAYERS
10.5.5 PARTICIPANTS
FIGURE 28 GLOBAL MARKET: COMPETITIVE LEADERSHIP MAPPING, 2021
10.6 COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES (2021)
10.6.1 PROGRESSIVE COMPANIES
10.6.2 STARTING BLOCKS
10.6.3 RESPONSIVE COMPANIES
10.6.4 DYNAMIC COMPANIES
FIGURE 29 MARKET: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES, 2021
10.7 COMPETITIVE SCENARIO
10.7.1 PRODUCT LAUNCHES & APPROVALS
TABLE 193 PRODUCT LAUNCHES & APPROVALS (2020-2022)
10.7.2 DEALS
TABLE 194 DEALS (2021-2022)
10.7.3 OTHER DEVELOPMENTS
TABLE 195 OTHER DEVELOPMENTS
11 COMPANY PROFILES (Page No. - 158)
11.1 KEY PLAYERS
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
11.1.1 ABBOTT LABORATORIES
TABLE 196 ABBOTT LABORATORIES: BUSINESS OVERVIEW
FIGURE 30 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021)
11.1.2 ROCHE DIAGNOSTICS
TABLE 197 ROCHE DIAGNOSTICS: BUSINESS OVERVIEW
FIGURE 31 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2021)
11.1.3 HOLOGIC, INC.
TABLE 198 HOLOGIC, INC.: BUSINESS OVERVIEW
FIGURE 32 HOLOGIC, INC: COMPANY SNAPSHOT (2021)
11.1.4 BECTON, DICKINSON AND COMPANY
TABLE 199 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
FIGURE 33 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021)
11.1.5 QUEST DIAGNOSTICS
TABLE 200 QUEST DIAGNOSTICS: BUSINESS OVERVIEW
FIGURE 34 QUEST DIAGNOSTICS: COMPANY SNAPSHOT (2021)
11.1.6 QIAGEN N.V.
TABLE 201 QIAGEN N.V.: BUSINESS OVERVIEW
FIGURE 35 QIAGEN N.V.: COMPANY SNAPSHOT (2021)
11.1.7 SEEGENE, INC.
TABLE 202 SEEGENE, INC: BUSINESS OVERVIEW
11.1.8 FEMASYS, INC.
TABLE 203 FEMASYS, INC.: BUSINESS OVERVIEW
11.1.9 ARBOR VITA CORPORATION
TABLE 204 ARBOR VITA CORPORATION: BUSINESS OVERVIEW
11.1.10 MYLAB DISCOVERY SOLUTIONS PVT. LTD.
TABLE 205 MYLAB DISCOVERY SOLUTIONS PVT. LTD.: BUSINESS OVERVIEW
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
11.2 OTHER PLAYERS
11.2.1 EVERLYWELL INC.
TABLE 206 EVERLYWELL INC.: COMPANY OVERVIEW
11.2.2 NURX INC.
TABLE 207 NURX INC.: COMPANY OVERVIEW
11.2.3 DALRADA CORPORATION
TABLE 208 DALRADA CORPORATION: COMPANY OVERVIEW
11.2.4 NEODIAGNOSTIX
TABLE 209 NEODIAGNOSTIX: COMPANY OVERVIEW
11.2.5 JIANGSU MOLE BIOSCIENCE CO., LTD.
TABLE 210 JIANGSU MOLE BIOSCIENCE CO., LTD.: COMPANY OVERVIEW
11.2.6 SANSURE BIOTECH INC.
TABLE 211 SANSURE BIOTECH, INC.: COMPANY OVERVIEW
12 APPENDIX (Page No. - 183)
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 CUSTOMIZATION OPTIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
Methodology
The study involved major activities in estimating the current market size for the global HPV testing and Pap test market.
Exhaustive secondary research was done to collect information on the HPV testing and Pap test market. The next step was to validate these findings, assumptions, and sizes with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the HPV testing and Pap test market.
Four steps involved in estimating the market size are as follows:
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to in order to identify and collect information for this study.
Primary Research
In the primary research process, various sources from the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.
The following is a breakdown of the primary respondents:
Note 1: Others include sales, marketing, and product managers.
Note 2: Companies are classified into tiers based on their total revenue. As of 2024, Tier 1 = > USD 100 million, tier 2 = USD 10 million to USD 100 million, and tier 3 = < USD 10 million
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both the top-down and bottom-up approaches were used to estimate and validate the HPV testing and Pap test market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size included the following:
- The key players in the industry have been identified through extensive secondary research.
- The revenues generated by leading players operating in the HPV testing and Pap test market have been determined through primary and secondary research.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
The research methodology used to estimate the market size included the following:
Data Triangulation
After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Human Papillomavirus (HPV) testing identifies the presence of high-risk HPV strains that can lead to cervical cancer and related abnormalities. It is increasingly adopted as a primary screening approach, either independently or alongside Pap testing (co-testing), to assess the risk of cervical disease.
The Papanicolaou (Pap) test is a cytological screening procedure used to detect precancerous and cancerous cells in the cervix, which connects the uterus and vagina. While primarily applied in cervical cancer screening, Pap tests can also detect abnormal or malignant cells in the vaginal canal in some cases.
Stakeholders
- Senior Management
- End Users
- Finance/Procurement Department
- R&D Department
Report Objectives
- To define, describe, segment, and forecast the global HPV testing and Pap test market by product & service, test type, technology, application, care setting, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall HPV testing and Pap test market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
- To benchmark players within the HPV testing and Pap test market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offerings
- To study the impact of AI/Gen AI on the market, along with the macroeconomic outlook for each region
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free Customisation
Before You Go
Expand Beyond Human Papilloma Virus/HPV Test and Pap Smear/Test Market
Explore the top 20 industries influencing your market growth
Human and AI Powered Market Intelligence
Find Untapped Markets
Growth opportunities and latent adjacency in Human Papilloma Virus/HPV Test and Pap Smear/Test Market